Bristol Myers Squibb (CELG-RI) Enterprise Value Growth (3y) (2012 - 2026)

Bristol Myers Squibb (CELG-RI) Enterprise Value Growth (3y) (2012 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Bristol Myers Squibb 244.56 Mn -10.21 Bn 8.07 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 -4.32%
Dec 31, 2025 -4.98%
Sep 30, 2025 -22.44%
Jun 30, 2025 -0.96%
Mar 31, 2025 7.69%
Dec 31, 2024 13.86%
Sep 30, 2024 19.82%
Jun 30, 2024 20.03%
Mar 31, 2024 9.25%
Dec 31, 2023 8.14%
Sep 30, 2023 28.77%
Jun 30, 2023 26.22%
Mar 31, 2023 20.40%
Dec 31, 2022 15.59%
Sep 30, 2022 34.86%
Jun 30, 2022 23.36%
Mar 31, 2022 -19.81%
Dec 31, 2021 -24.97%
Sep 30, 2021 -32.39%
Jun 30, 2021 -29.27%